Breakthrough in ME/CFS Research: Antibodies from Patients Target Healthy Cell Mitochondria
A groundbreaking study funded by ME Research UK has uncovered a key mechanism in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), revealing that immunoglobulin G (IgG) antibodies from patients with post-infectious ME/CFS can directly disrupt mitochondrial function in healthy human cells. Mitochondria, often called the 'powerhouses of the cell,' are essential for producing adenosine triphosphate (ATP), the energy currency required for nearly all cellular processes. This discovery provides compelling evidence of an autoimmune component driving the debilitating fatigue and post-exertional malaise (PEM) characteristic of ME/CFS.
The research, published in Brain, Behavior, & Immunity - Health in early 2026, demonstrates how these antibodies induce mitochondrial fragmentation and alter energy metabolism specifically in endothelial cells, which line blood vessels and play a critical role in circulation and oxygen delivery. This finding builds on years of hints at mitochondrial dysfunction in ME/CFS and opens new avenues for diagnostics and treatments.
Understanding ME/CFS: A Complex Post-Infectious Illness
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a multisystem disease typically triggered by viral or bacterial infections, affecting an estimated 400,000 people in the UK alone, according to recent prevalence studies using NHS data. Symptoms include profound fatigue not relieved by rest, PEM where minimal activity leads to symptom crashes lasting days or weeks, cognitive impairments ('brain fog'), unrefreshing sleep, orthostatic intolerance, and pain. Diagnosis relies on clinical criteria like the Institute of Medicine (IOM) or International Consensus Criteria (ICC), as no single biomarker exists.
In the UK, lifetime prevalence is around 0.6%, with women disproportionately affected (0.92% vs 0.25% in men). Post-COVID ME/CFS (also called post-viral fatigue syndrome) has surged cases, straining healthcare. The economic burden exceeds £3.3 billion annually in direct and indirect costs, including lost productivity, as up to 25% of patients are housebound or bedbound.
The Central Role of Mitochondria in Cellular Energy and ME/CFS
Mitochondria generate ATP through oxidative phosphorylation (OXPHOS) in the electron transport chain (ETC), housed in cristae folds. They also regulate calcium signaling, reactive oxygen species (ROS), and apoptosis. In ME/CFS, prior studies consistently report mitochondrial abnormalities: reduced ATP production, impaired ETC activity, elevated lactate, fragmented networks, and oxidative stress.
A systematic review of 19 studies confirmed structural changes like irregular cristae and functional deficits across blood, muscle, and immune cells. These align with PEM, where energy demand overwhelms supply. If you are exploring careers in biomedical research, opportunities in mitochondrial studies abound at UK universities through research jobs.
Step-by-step, mitochondrial dysfunction unfolds: 1) Infection triggers immune activation; 2) ROS damages mtDNA/proteins; 3) Fragmentation via Drp1/fission proteins; 4) Reduced OXPHOS shifts to glycolysis (Warburg-like effect); 5) Lactate buildup causes fatigue/acidosis.
Study Design: Probing Autoantibodies' Effects on Healthy Cells
Led by Prof. Bhupesh K. Prusty at Riga Stradiņš University (Latvia) and University of Würzburg (Germany), the team analyzed IgG from 106 individuals: 39 ME/CFS, 15 post-COVID ME/CFS (PCS-CFS), 20 multiple sclerosis (MS), and 41 healthy donors (HD). IgG was purified and applied to primary human umbilical vein endothelial cells (HUVECs), fibroblasts (HFFs), and peripheral blood mononuclear cells (PBMCs).
Methods included confocal microscopy for morphology, Seahorse assays for bioenergetics, proteomics on immune complexes, and multiplex ELISA for cytokines. Fab/Fc fragments tested specificity. The project stems from ME Research UK's 2021 grant to investigate infectious triggers and mitochondrial dysfunction.ME Research UK Project Page
Key Findings: Mitochondrial Fragmentation and Energetic Shifts
ME/CFS IgG caused dose- and time-dependent mitochondrial fragmentation in HUVECs (reduced area/network length, P<0.001), downregulated fusion proteins (Drp1, Mitofilin), but no mitophagy increase. Stronger in female patients. Fab fragments replicated effects, indicating antigen-binding specificity.
- Increased basal respiration and spare capacity (glucose media), suggesting compensatory hypermetabolism without ATP loss.
- In galactose (OXPHOS-forced), effects masked, highlighting glycolysis reliance.
- PBMCs showed elevated IL-1β (P=0.046), trends in pro-inflammatory cytokines.
- Proteomics: ECM remodeling (ME/CFS), hemostasis changes (PCS-CFS).
Full paper: DOI: 10.1016/j.bbih.2026.101187
Photo by Dessy Dimcheva on Unsplash
Building on a Foundation of Mitochondrial Research in ME/CFS
This aligns with meta-analyses showing consistent deficits across cohorts: lower OXPHOS in PBMCs/muscle, mtDNA damage, ROS elevation. Earlier Prusty work linked herpesviruses to fragmentation via cell danger response. Unlike MS controls, effects are disease-specific, supporting autoimmunity hypothesis.
Pathophysiological Implications: Linking Antibodies to Symptoms
Endothelial mitochondrial disruption impairs vasodilation/oxygen delivery, explaining orthostasis/PEM. Female bias matches epidemiology. Chronic IgG-driven stress induces adaptive fragmentation, trapping cells in low-energy state. PCS-CFS shows inflammatory phase transitioning to metabolic in chronic ME/CFS.
Stakeholders like ME Research UK hail it as 'biological evidence' for targeted therapies.ME Research UK
Therapeutic Horizons: Targeting Mitochondria and Autoantibodies
Potential interventions: IVIG to remove pathogenic IgG (trials ongoing), mitochondrial nutrients (CoQ10, NADH), antioxidants, or fusion promoters (M1/Miga1 agonists). Nutraceutical reviews show promise in subsets. Plasmapheresis or B-cell depletion (rituximab-like) could help. For researchers, academic career advice on grant writing for such projects is vital.
UK's Commitment to ME/CFS Research Landscape
ME Research UK, a Scottish charity, funds high-risk biomedical projects. UK initiatives: DecodeME (Edinburgh Uni, largest genetic study), UCL biobank for biomarkers, NIHR grants. 2025 govt delivery plan boosts research amid £3bn+ burden. Conferences like BRMEC15 (2026) foster collaboration.
Voices from Experts, Patients, and Researchers
Prof. Prusty: 'IgGs carry a chronic protective stress response promoting mitochondrial adaptation.' Patients report hope: 'Validates our energy crash.' Experts note subgroup effects limit generalizability but advance autoimmunity model.
Photo by Navy Medicine on Unsplash
Future Directions and Calls to Action
Next: Biomarker validation, longitudinal cohorts, trials. UK unis can lead via research assistant jobs. Explore professor ratings on Rate My Professor, pursue higher ed jobs in biomed, or career advice. Stay informed for breakthroughs.